PMID: 6104795May 1, 1980Paper

Evidence for an irreversible interaction of bromocryptine with central dopamine receptors

Naunyn-Schmiedeberg's Archives of Pharmacology
M J BannonR H Roth

Abstract

The effects of the dopamine agonist bromocryptine on several measures dopaminergic function were assessed in the rat. Following inhibition of impulse flow with gamma-butyrolactone, and after dopa decarboxylase inhibition, dopa accumulation and its reversal by dopamine agonists is easily studied. In this model, bromocryptine (10 mg/kg, i.p.) caused a significant decrease in dopa accumulation in both the striatum and olfactory tubercle which was prevented, but not reversed, by the dopamine antagonist (+)-butaclamol (4 mg/mg, i.p.). The inactive isomer, (-)-butaclamol was without effect. Analysis of an vitro 3H-spiperone binding 2h after bromocryptine (10 mg/kg, i.p.) revealed a 30% decrease in the number of striatal dopamine receptors labelled (Bmax), with no change in receptor affinity for 3H-spiperone. No changes in binding were seen when animals were sacrificed 30 min or 48 h after bromocryptine. In extracellular single unit recording experiments, bromocryptine-induced depression of nigrostriatal dopamine cell firing was found to be largely reversible by the dopamine antagonist haloperidol when injected within 5 min of intravenous bromocryptine. However, when haloperidol was injected more than 20 min after bromocryptine, no re...Continue Reading

References

Dec 29, 1976·Naunyn-Schmiedeberg's Archives of Pharmacology·J R Walters, R H Roth
Dec 1, 1977·Life Sciences·E E MůllerP Mantegazza
Jan 1, 1979·Dental Hygiene·C Palmer
Dec 15, 1977·European Journal of Pharmacology·I CreeseS H Snyder
Apr 10, 1965·Nature·R C Thomas, V J Wilson
Jan 1, 1972·Naunyn-Schmiedeberg's Archives of Pharmacology·W KehrM Lindqvist
Mar 20, 1966·Journal of the American Chemical Society·H OttA J Frey

❮ Previous
Next ❯

Citations

Jan 1, 1981·Psychopharmacology·R L WeirE K Silbergeld
Jan 1, 1987·Journal of Neural Transmission·D M Jackson, M Hashizume
Jan 1, 1985·Journal of Neural Transmission·D M Jackson, O F Jenkins
Jul 30, 1982·European Journal of Pharmacology·A M HoloheanJ B Appel
Apr 13, 1984·European Journal of Pharmacology·D A BergstromJ R Walters
Mar 16, 1984·European Journal of Pharmacology·M J CroninM O Thorner
Feb 1, 1986·Pharmacology, Biochemistry, and Behavior·F J White
Aug 1, 1989·Pharmacology, Biochemistry, and Behavior·K KumorJ Jaffe
Jan 1, 1983·Neuroscience and Biobehavioral Reviews·J N Joyce
Jan 1, 1994·Pharmacology & Therapeutics·D M Jackson, A Westlind-Danielsson
Jul 11, 2002·European Journal of Pharmacology·Giorgio MarcheseLuca Pani
Jan 1, 1984·Journal of Neurochemistry·I S Hoffmann, L X Cubeddu
Apr 1, 1985·Medicinal Research Reviews·C Kaiser, T Jain
Oct 1, 1981·The Journal of Pharmacy and Pharmacology·P R Sanberg, I Creese

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here